NCT05393245View on ClinicalTrials.gov

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

CompletedOBSERVATIONAL
Enrollment

19,467

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium+Olodaterol

Tiotropium+Olodaterol

DEVICE

Spiolto Respimat

Spiolto Respimat Inhaler device

DRUG

Long-acting muscarinic antagonists (LAMAs)

Long-acting muscarinic antagonists (LAMAs)

DRUG

Long-acting β2-agonists (LABAs)

Long-acting β2-agonists (LABAs)

Trial Locations (1)

10617

Health Data Research Center, National Taiwan University, Taiwan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data | Biotech Hunter | Biotech Hunter